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Key Clinical Message
BRCA1, c.4096+3A>G was identified in a consanguineous Danish family with
several cases of breast/ovarian cancer. In silico analysis and splicing assays indi-
cated that the variant caused aberrant splicing. However, based on segregation
data and the finding of a healthy homozygous carrier, we classify the BRCA1
c.4096+3A>G variant as likely benign.
Keywords
BRCA1, classification, genetics, oncology.
Germline mutations in the breast cancer gene 1 [BRCA1,
MIM# 604370] is associated with a lifetime risk of 40–
87% for developing breast cancer and a 22–65% lifetime
risk of developing ovarian cancer in women [1]. Male
BRCA1 carriers do not seem to have a significantly
increased risk of cancer, however, some studies show a
trend toward an increased risk of prostate cancer [2, 3].
More than 5000 variants in the BRCA1 gene have been
identified (BRCA Exchange and ClinVar databases: http://
brcaexchange.org/; https://www.ncbi.nlm.nih.gov/clinvar/?
term=brca1%5Bgene%5D) through mutational screening
as BRCA1 was identified and cloned more than 20 years
ago [4]. Variants can be classified into five classes, where
Class 1 encompass variants that are “not pathogenic” or
of “no clinical significance,” Class 2 includes variants that
are “likely not pathogenic” or of “little clinical signifi-
cance,” Class 3 are variants which are of “uncertain clini-
cal significance” (VUS), the variants in Class 4 are “likely
pathogenic,” and the Class 5 variants are qualitatively
described as “definitely pathogenic” [5, 6]. The ENIGMA
consortium (Evidence-based Network for the Interpreta-
tion of Germline Mutant Alleles) has tailored the IARC
5-tier classification system specifically to the assessment of
BRCA1/2 variants by incorporating information from
splicing assays, in silico data, cosegregation data as well as
data regarding co-occurrence in trans with a known
pathogenic mutation [7]. In April 2016, the ENIGMA
consortium had received more than 3000 submissions of
individual VUS in BRCA1/2 [8], underlining the need for
further research in this field.
In silico programs can to some extent predict the
expected consequence of a VUS, however to classify vari-
ants as pathogenic or benign cosegregation analysis or
functional analyses must be applied.
A large number of BRCA1 variants were recently found
to cause abnormal splicing [9]. Variants in the consensus
acceptor and donor splice site are usually creating an
abnormal splicing pattern resulting in an mRNA that is
degraded by nonsense-mediated decay [10]. For intron
variants located close to the splice site, in silico programs
can help ascertain the effect of the variant, but in order
to classify intron variants, functional analysis such as RT-
PCR of RNA from blood samples or minigene assays
must be performed [11, 12]. Even when an abnormal
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mRNA transcript is produced, it can be a challenge to
determine whether this transcript is of clinical relevance
or an event that occurs in a normal cell [13].
Rosenthal et al. [14] reclassified three variants, one in each
of the BRCA1, BRCA2, and MSH2 genes, all initially sus-
pected of being pathogenic. Based on additional family his-
tory, testing and/or renewed search in the literature, these
variants were classified as benign or intermediate risk. Fur-
thermore, they concluded that there is a need for a discus-
sion of how to handle reevaluation of variants and where the
responsibility for informing affected family members lie [14].
Here, we present a case in which a spliceogenic BRCA1
variant is classified as likely benign after further genetic
testing in the family.
We report a consanguineous Danish family with multi-
ple cases of breast cancer and ovarian cancer (Fig. 1). The
proband (V:2) was diagnosed with a borderline mucinous
cystadenoma of the ovary at the age of 35 years and was
referred to genetic counseling. At the age of 45, the
patient additionally developed a squamous cell carcinoma
on the left side of her back. The borderline mucinous cys-
tadenoma does not fall into the BRCA1 phenotype spec-
trum; however, being a first degree relative to a breast
cancer patient in a family with a history of breast and
ovarian cancer, further investigation was indicated. The
BRCA1 and BRCA2 genes were sequenced, and a
heterozygous variant was identified at the third nucleotide
in the intron sequence after exon 11 in the BRCA1 gene
(c.4096+3A>G). The variant was localized in close prox-
imity of exon 11’s donor splice site, and in silico splicing
prediction (MaxEntScan) indicated that the variant
destroyed the donor splice site. Deletion/duplication anal-
yses by multiplex ligation-dependent probe amplification
(MLPA) of the BRCA1 and BRCA2 genes were also per-
formed with a normal result.
Previous RT-PCR analysis on RNA from blood samples
has shown that the BRCA1 c.4096+3A>G variant
increased skipping of BRCA1 exon 11 (c.671_4096del)
and increased expression of Δ11q, an isoform using an
internal splice donor site at c.788 in exon 11 in contrast
to control samples [15]. However, the allele-specific tran-
script expression was not assessed. Moreover, the presence
of naturally occurring BRCA1 isoforms lacking exon 11
has recently been described [13], adding to the complex-
ity of assessing the effect of the variant.
In the ClinVar database, reports classify the variant as
either pathogenic, likely pathogenic or as a VUS, however
using the ENIGMA classification system, we initially clas-
sified the variant as a VUS (Class 3). Therefore to further
clarify the role of the BRCA1 c.4096+3A>G variant, we
decided to test other family members to see if the variant
segregated with breast/ovarian cancer. However, the fam-
ily members were informed that the variant was of uncer-
tain significance beforehand. Family members who had
inherited the variant were offered surveillance programs
according to national guidelines for mutation carriers,
whereas family members who had not inherited the vari-
ant were risk evaluated based on the family pedigree. The
index patient’s cousin (V:6), who had developed breast
cancer at the age of 47, was tested and she did not carry
Figure 1. The pedigree of the family is shown and the diagnosis is noted under each individual with the age of diagnosis. □ : Male. ○ : Female.
+ : Carrier of the BRCA1 c.4096+3A>G variant. – Not a carrier of the BRCA1 c.4096+3A>G variant.
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the variant. Complete screening of BRCA1, BRCA2,
PTEN, RAD51C, TP53, and CDH1 was performed, and
no pathogenic mutations were identified.
A 58-year-old healthy cousin of the index patients
mother (IV:7) was tested and found to be homozygous
for the BRCA1 c.4096+3A>G variant (Fig. 2). The finding
was verified by the use of two sets of PCR primers as well
as target sequence capture followed by NGS analysis.
Clinical examination of the cousin revealed a single cafe-
au-lait spot on her right crus (present from early child-
hood), and no congenital malformations, no mental retar-
dation or dysmorphic features, normal extremities, and
especially normal thumbs with no additionally fingers or
toes. Her height was 164 cm, corresponding to the height
of her parents, and she had normal educational background
and worked in the same research office for 40 years. A stan-
dard chromosome analysis was performed, showing a nor-
mal female karyotype and no visible chromosomal breakage.
She was related to the proband both on paternal side
(III:8) but also on her maternal side (III:9) as her parents
were first cousins. Her mother (III:9) was a carrier of the
BRCA1 c.4096+3A>G variant, and she was 87 years old and
without cancer. It was not possible to test the father, but he
was an obligate carrier based on the pedigree. This case is
an example of a BRCA1 variant which is assessed possibly
pathogenic due to data from in silico predictions and splic-
ing assays, but in which family testing revealed that the
variant did not segregate with the disease and even more
important a healthy 58-year-old female relative was shown
to be homozygous for the BRCA1 c.4096+3A>G variant
(IV:7). Biallelic mutations in the BRCA1 gene are very rare,
and they cause severe disease, for example Fanconi Anemia,
which is characterized by growth retardation, skeletal and
organ malformation, aplastic anemia (caused by bone mar-
row failure), and increased risk of cancer development
(particularly leukemias) [16, 17]. Besides a single “cafe-au-
lait” spot, the clinical examination of IV:7 revealed none
characteristics seen in Fanconi Anemia. In this case, IV:7
was homozygous for the BRCA1 variant, and homozygosity
for a pathogenic BRCA1 mutation has traditionally been
considered incompatible with life. Therefore, the likelihood
that the BRCA1 c.4096+3A>G variant is pathogenic is con-
sidered to be low. We therefore reclassified the variant as a
class 2 variant according to the IARC 5-tier classification
system, even though reduced penetrance of the variant can-
not be excluded. In this regard, it should be noted that any
BRCA1 allele that permits 20–30% of tumor suppressor
function recently has been suggested not to increase the risk
of breast or ovarian cancer [18]. Correct evaluation of
novel variants in genes associated with cancer is crucial in
order to give patients and family members the correct treat-
ment/surveillance. This is particularly important in a time
where the use of exome/genome sequencing is increasing
and as a consequence of this so are the number of reported
variants in high-risk cancer genes. Ideally, a more elaborate
setup should be rolled out, for example including func-
tional analyses if possible (RNA sequencing or at protein
level e.g., evaluating protein–protein interactions) when
assessing a novel variant [19]. If functional analyses were
performed, the nature of a novel variant may be assessed
correctly initially, but this setup is not always possible at
least in a diagnostic laboratory. If the nature of the variant
cannot be assessed through further analyses Rosenthal et al.
[14] suggests a compromise in which to opt for surveillance
programs but not preventive surgeries. Family studies with
cosegregation analysis are not always possible, but this
reported case illustrates the importance of including this
aspect in the assessment of pathogenicity of variants.
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